This study is for patients that have been diagnosed with non-squamous non-small cell lung cancer. The purpose of this study is to evaluate the objective response rate (ORR) (confirmed and unconfirmed, complete and partial) with talazoparib plus avelumab in patients with Stage IV or recurrent non-squamous non-small cell lung cancer bearing pathogenic STK11 genomic alterations that were previously-treated with anti-PD-1/PD-L1 therapy and platinum-based chemotherapy. The investigational drugs used in this study are talazoparib and avelumab. Talazoparib and avelumab are drugs that may increase the ability of your immune system to fight lung cancer. Participants can expect to be on this study until disease progression, the side effects come to severe or they choose to discontinue the study. Participants will be followed by the study doctor for up to 3 years.

This study is for patients who have RET Fusion-Positive Stave IV or Recurrent Non-Small Cell Lung Cancer. The purpose of this study is to see if we can lower the chance of RET Fusion-Positive Advanced Non-Small Cell Lung Cancer growing or spreading by using the study drug selpercatinib (LOXO-292). Selpercatinib (LOXO-292) is a drug that inhibits RET, a biomarker present in your tumor. Participants will be on this study until disease progression, the side effects become too severe or until they choose to discontinue the study. Participants will be followed by the study doctor for up to 3 years.

This study is for patients that have been diagnosed with non-small cell lung cancer that has spread outside of the lungs, and the tumor sample has a biomarker which is positive for LOH (loss of heterozygosity) or BRCA1/2 mutations. The purpose of this study is to test the good and bad effects of the study drug, rucaparib. Rucaparib is a drug that works by slowing or stopping the growth of cancer cells. Patients can expect to be on this study until disease progression or until the side effects become too severe. Patients will then be followed by their study doctor for up to 3 years after study completion.

This study is for patients previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer. The purpose of this study is to compare the usual treatment (standard of care) to using ramucirumab plus pembrolizumab (study drug). Patients can expect to be on this study until disease progression or until the side effects become too severe. Patients will then be followed by their study doctor for up to 3 years after study completion.

Physicians currently have difficulty getting a biopsy of lung spots that are far from the center of the lung. The bronchoscopes that are currently used to reach these spots are sometimes difficult to maneuver and are unable to reach these spots. This study will test the performance of a new robotic bronchoscope that uses navigation software to find the distant spots in the lung so physicians can successfully get a biopsy.

This study is for patients who have been diagnosed with solid tumor malignancy with KRAS G12C mutation. The investigational drug used in this study is MRTX849. The purpose of this study is to see if patients with cancer with a KRAS G12C mutation will benefit from treatment with MRTX849, what side effects occur and how often they occur and to see how quickly MRTX849 is absorbed into the blood stream and how fast it is removed by the body. Participants can expect to be in this study for as long as the disease does not get worse.

This study is for patients that have been diagnosed with non-small cell lung cancer. The purpose of this study is to find out if a targeted immunotherapy treatment will have an effect on specific genes and proteins in tumors. This is a screening study in which a tumor sample will be submitted for testing. Based on results, the participant will be assigned to one of the treatment sub-studies.

This study is for patients that have been diagnosed with Small-Cell Lung Cancer. The purpose of this study is to find out if this approach is better or worse than the usual approach. The usual approach is defined as care that most people get for small cell lung cancer. Participants can expect to be on this study for two years.

This study is for patients that have been diagnosed with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (NSCLC). The investigational drug used in this study is durvalumab. This purpose of this study is to see how if durvalumab will work and be safe for the treatment of patients with Stage I/II Non Small Cell Lung Cancer following stereotactic body radiation therapy when compared to placebo. Participants can expect to be in the study for approximately 6 years.

This study is for patients that have been diagnosed with Resectable Stages II and III Non-small Cell Lung Cancer (NSCLC). The investigational drug in this study is durvalumab. The purpose of this study is to see if durvalumab will work and be safe for the treatment of resectable NSCLC. Participants can expect to be on this study for about 5 years.